Shares of Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $206.3571.
ALGN has been the topic of several research analyst reports. Leerink Partners raised their price target on Align Technology from $225.00 to $230.00 in a research report on Thursday, April 30th. Zacks Research cut Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. Evercore increased their target price on Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Wall Street Zen raised Align Technology from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Finally, Citigroup began coverage on Align Technology in a research report on Wednesday, April 15th. They issued a “buy” rating and a $240.00 price target on the stock.
View Our Latest Stock Analysis on ALGN
Hedge Funds Weigh In On Align Technology A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. boosted its holdings in Align Technology by 37.2% in the 1st quarter. Bessemer Group Inc. now owns 247 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 67 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. grew its position in Align Technology by 3.7% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 1,896 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 68 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Align Technology by 77.5% during the 1st quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 69 shares during the period. Comerica Bank increased its holdings in shares of Align Technology by 0.6% during the 4th quarter. Comerica Bank now owns 13,656 shares of the medical equipment provider’s stock worth $2,132,000 after purchasing an additional 76 shares during the period. Finally, First Bank & Trust raised its position in shares of Align Technology by 5.0% during the second quarter. First Bank & Trust now owns 1,599 shares of the medical equipment provider’s stock valued at $270,000 after buying an additional 76 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.
Align Technology Trading Down 0.7% NASDAQ:ALGN opened at $167.01 on Thursday. Align Technology has a 1 year low of $122.00 and a 1 year high of $208.30. The firm’s fifty day simple moving average is $173.31 and its 200 day simple moving average is $175.01. The firm has a market capitalization of $11.96 billion, a PE ratio of 28.02, a PEG ratio of 1.71 and a beta of 1.67.
Align Technology (NASDAQ:ALGN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The medical equipment provider reported $2.58 EPS for the quarter, topping the consensus estimate of $2.26 by $0.32. Align Technology had a net margin of 10.50% and a return on equity of 15.82%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm posted $2.13 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, analysts anticipate that Align Technology will post 9.48 EPS for the current fiscal year.
Align Technology announced that its board has authorized a stock repurchase plan on Wednesday, April 29th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 1.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
About Align Technology (Get Free Report)
Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.
The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.
Featured Stories Five stocks we like better than Align Technology Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBrokerages Set Graphic Packaging Holding Company (NYSE:GPK) Price Target at $11.03
NEXT HEADLINE »Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts
Key Takeaways ALGN is expanding globally, with double-digit Clear Aligner volume growth across EMEA and APAC regions. ALGN is strengthening digital dentistry through iTero platform enhancements and workflow software innovation. ALGN faces foreign exchange and macroeconomic pressures that continue to weigh on margins and costs. Align Technology’s (ALGN - Free Report) international expansion efforts to broaden the business are poised to bring significant growth in the upcoming quarters. Also, iTero is gaining from the rapidly evolving intraoral scanning technology in the industry. However, a dull macroeconomic environment and unfavorable foreign exchange movements raise concerns about the company’s sales growth.
In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 11.1% against 11.9% growth of the industry. In contrast, the S&P 500 composite has risen 21.9%.
The renowned medical device company has a market capitalization of $11.26 billion. ALGN projects a long-term estimated earnings growth rate of 10.3% compared with 9.6% for the industry. Its earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 7.8%.
Let’s delve deeper.
Upsides for ALGN StockGeographic Expansion Continues: Align Technology is expanding its sales and marketing reach by entering new countries and regions, including previously unexplored areas in Africa and Latin America. At the end of 2025, the company has 13 fabrication and treatment locations throughout the world.
In the EMEA region, Clear Aligner volumes grew double digits year over year, led by increases in Iberia, Italy, Nordics, United Kingdom and Turkey. Growth was driven primarily by utilization gains across both GP and orthodontic channels. In APAC, Clear Aligner volumes also grew double digits year over year, led by China, India, Korea, Japan, India and Taiwan. Growth was broad-based, with teen and growing kid patient categories posting double-digit growth alongside continued growth among adult patients.
iTero in Focus: ALGN’s iTero intraoral scanners, alongside its Exocad CAD/CAM software, continue to gain traction globally as key tools in digital dentistry. iTero scanning remains central to digital workflows, enabling precise treatment planning and visualization.
Additionally, new innovations, including the Invisalign Outcome Simulator Pro, iTero Design Suite, and Align Oral Health Suite, are being used to enhance diagnostic, restorative and orthodontic workflows. Recently, the company has introduced a set of enhancements to its iTero Digital Solutions platform — a comprehensive system that puts together intra-oral scanners, software tools and digital workflows used by dental and orthodontic practices.
Image Source: Zacks Investment Research
What Ails ALGN?Currency Headwinds: Foreign exchange is a major headwind for Align Technology due to a considerable percentage of its revenues coming from outside the United States. Time to time, Clear Aligner Average Selling Prices (“ASP”) are significantly impacted by unfavorable foreign exchange across multiple currencies, especially the Japanese yen, Euro and Brazilian real. First-quarter gross margin was unfavorably impacted by foreign exchange of 0.4 points year over year.
Macroeconomic Concerns: Align Technology continues to navigate macroeconomic pressures, including inflation-driven increases in labor and freight costs, staffing shortages and ongoing supply-chain challenges — factors that are affecting profitability across the elective dental treatment space. In the first quarter of 2026, these issues led to a 1.4% increase in the company cost of sales.
ALGN Stock Estimate TrendThe Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $11.36 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $4.19 billion, suggesting a 3.7% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Alcon (ALC - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Alcon has an earnings yield of 5.1% against the industry’s negative 2.8% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. ALC’s earnings topped estimates in three of the trailing four quarters and missed in one, the average surprise being 3.7%.
ALC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
TEMPE, Ariz & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced new innovations across its integrated Align™ Digital Platform*, designed to help doctors visualize, plan, and treat with greater confidence and predictability. Throug.
California Public Employees Retirement System cut its stake in shares of Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 2.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 120,619 shares of the medical equipment provider’s stock after selling 3,016 shares during the period. California Public Employees Retirement System owned about 0.17% of Align Technology worth $20,678,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sequoia Financial Advisors LLC increased its stake in shares of Align Technology by 320.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 7,986 shares of the medical equipment provider’s stock worth $1,247,000 after purchasing an additional 6,085 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Align Technology by 35,513.8% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 545,604 shares of the medical equipment provider’s stock worth $85,196,000 after purchasing an additional 544,072 shares during the period. Polianta Ltd purchased a new position in Align Technology during the fourth quarter valued at $1,623,000. Wealth Enhancement Advisory Services LLC lifted its position in Align Technology by 63.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 25,343 shares of the medical equipment provider’s stock valued at $4,282,000 after purchasing an additional 9,792 shares in the last quarter. Finally, Hunter Perkins Capital Management LLC grew its holdings in Align Technology by 383.1% during the fourth quarter. Hunter Perkins Capital Management LLC now owns 43,842 shares of the medical equipment provider’s stock valued at $6,846,000 after purchasing an additional 34,767 shares during the period. 88.43% of the stock is owned by institutional investors.
Align Technology Stock Down 2.8% Shares of Align Technology stock opened at $172.46 on Thursday. The company has a market capitalization of $12.35 billion, a price-to-earnings ratio of 28.94, a PEG ratio of 1.82 and a beta of 1.67. The stock’s 50-day simple moving average is $172.96 and its 200-day simple moving average is $174.98. Align Technology, Inc. has a 52 week low of $122.00 and a 52 week high of $208.30.
Align Technology (NASDAQ:ALGN – Get Free Report) last released its earnings results on Wednesday, April 29th. The medical equipment provider reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.32. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Align Technology had a return on equity of 15.82% and a net margin of 10.50%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.13 earnings per share. On average, equities analysts expect that Align Technology, Inc. will post 9.48 earnings per share for the current year.
Align Technology declared that its board has approved a stock repurchase program on Wednesday, April 29th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 1.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.
Analyst Ratings Changes ALGN has been the subject of a number of analyst reports. Weiss Ratings upgraded Align Technology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 17th. Zacks Research cut Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 16th. Evercore boosted their price objective on Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Piper Sandler increased their target price on shares of Align Technology from $220.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, April 21st. Finally, Leerink Partners raised their target price on shares of Align Technology from $225.00 to $230.00 in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Align Technology currently has an average rating of “Moderate Buy” and an average target price of $206.07.
Check Out Our Latest Analysis on ALGN
About Align Technology (Free Report)
Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.
The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.
Featured Stories Five stocks we like better than Align Technology Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBoston Common Asset Management LLC Has $38.24 Million Stock Holdings in Broadcom Inc. $AVGO
NEXT HEADLINE »California Public Employees Retirement System Sells 13,519 Shares of Flutter Entertainment PLC $FLUT
Key Takeaways ALGN is set to report Q2 2026 results on July 29, with revenues expected to grow 3.9% year over year. ALGN's Clear Aligner segment is expected to benefit from higher volumes across regions and patient groups.Align Technology's digital tools, scanner adoption and ART pilot may support second-quarter revenue growth. Align Technology, Inc. (ALGN - Free Report) is set to release second-quarter 2026 results on July 29, after the closing bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.58, which surpassed the Zacks Consensus Estimate by 14.16%. Align Technology beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 7.80%.
ALGN’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $1.05 billion, which suggests 3.9% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.56 per share, which implies a 2.8% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q2 EarningsEstimates for second-quarter earnings have remained unchanged at $2.56 per share in the past 30 days.
Here’s a brief overview of the company’s performance leading up to this announcement.
The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, APAC and Latin America, with continued stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids. From a product standpoint, it is likely to have seen strong contributions from Invisalign First and the Invisalign Palatal Expander with Mandibular Advancement with Occlusal Blocks.
Dental and orthodontic service organizations (DSOs) must have remained a key, scalable growth channel in the to-be-reported quarter, with continued strong progress across all major regions. Meanwhile, the doctor subscription program (DSP), which includes retention, touch-up and relapse cases, is expected to have maintained strong momentum during the quarter.
The Zacks Consensus Estimate for Clear Aligner revenues indicates 6.3% year-over-year growth.
Align Technology, Inc. Price and EPS SurpriseImaging Systems & CAD/CAM Services (Systems and Services)
Within this segment, revenues are likely to have benefited from higher volumes across all regions and continued adoption of iTero Lumina scanner. In the first quarter, the total installed base of active scanners exceeded 125,000 globally. We expect this trend to have continued in the to-be-reported quarter as well.
exocad achieved strong revenue growth, reinforcing the company’s strategy to integrate orthodontics and restorative dentistry within a customer and patient-centric digital platform. We expect this trend to have persisted in the second quarter as well. Following the successful launch of Invisalign Advanced Restorative Treatment (ART) pilot in the EMEA, Align recently began an Invisalign ART pilot in the United States with labs and doctors beginning training in several markets. We expect the development to have contributed to the company’s top-line growth.
The company’s growing suite of digital diagnostic tools, including Align Oral Health Suite and Align X-ray Insights, helps doctors identify conditions earlier and deliver clearer, more informed treatment recommendations. We expect all these tools to have positively impacted Align Technology’s revenues in the second quarter.
The Zacks Consensus Estimate for the segment’s revenues implies a decrease of 5.5% on a year-over-year basis.
What Our Quantitative Model Predicts for ALGNPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:
Earnings ESP: Align Technology has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a LookHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Hinge Health Inc. (HNGE - Free Report) has an Earnings ESP of +4.24% and a Zacks Rank #1. The company is expected to release second-quarter 2026 results soon.
In the trailing four quarters, HINGE delivered an average surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago quarter’s figure.
Neurocrine Biosciences (NBIX - Free Report) has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.
NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure.
West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure.
Over six years, Align has contributed more than $2M to Operation Smile's student programs to send the next generation of global health advocates to the world stage
, /PRNewswire/ -- Operation Smile, a global nonprofit deeply committed to closing the gap in surgical and health care access, today announced Align Technology, Inc. (Nasdaq: ALGN) as the title sponsor of its 2026 International Student Leadership Conference (ISLC), marking the sixth consecutive year of this sponsorship. Through nearly $3.8 million in total contributions benefiting Operation Smile's students and surgical programs, Align Technology is a key global partner, supporting youth leadership and access to surgical care, demonstrating an enduring commitment to health care and the development of tomorrow's global health leaders.
ISLC 2026, the conference's 34th year, will take place in Bangkok, Thailand from July 17 – 23, 2026, bringing together approximately 280 high school and university participants from 37 countries. Through Align Technology's continued support, financial barriers are being removed for students with cleft conditions from low- and middle-income countries, creating a more inclusive and impactful global youth health movement.
An Impactful Year for Global Youth Leadership
ISLC 2026 is a testament to the unstoppable momentum of youth-led global health advocacy. Among the highlights of this year's conference:
280 total participants from high schools and universities ~100 scholarship recipients from all participating regions 10 participants attending under the Cleft Connect group scholarships, bringing their lived experience to lead and shape conversations within the global health movement Largest university cohort since the program reopened to university-level participants, with 37 university students attending 37 countries represented – a powerful signal of the program's ever-expanding global reach More than 90 participants from Asia, including students from China, the Philippines, Vietnam, India, and Thailand, with students from Nepal and Palestine joining for the first time, reflecting the depth of Operation Smile's impact across the region First cohort of Align Scholar recipients from the United States and Canada Bridging Barriers to Leadership
Through the Align Scholars program, approximately 100 students receive full scholarships covering travel and conference fees. Many of the Align Scholar program recipients were born with a cleft condition and the majority are from low- and middle-income countries.
"At Operation Smile, we believe the future of global health lies in the next generation," said Brigette Clifford, AVP Student Programs, Operation Smile. "Align Technology has been our most steadfast partner for six years. Their investments reflect their commitment to oral health and in young people's power to change the world. This year alone, approximately 100 students will attend ISLC knowing someone believed in them."
"Align Technology is proud to be a strong supporter of Operation Smile's life-changing work of to provide free surgeries and multi-modal care to people with cleft conditions," said Julie Paulsen, VP HR, Employee Programs, and Community Engagement, Align Technology. "The ISLC program, sponsored by Align, is a wonderful opportunity for students to develop leadership skills, positively impact their local communities, and raise awareness and advocacy of Operation Smile's remarkable programs around the world."
A 40+ Year Legacy, Accelerating Forward
Since its founding more than 40 years ago, Operation Smile has expanded access to life-changing surgical and health care across the globe, partnering with local medical leaders, health ministries, universities, and NGOs in more than 35 countries. The organization's bold commitment, Operation 100, is investing in local frontline health workers and strengthening district hospitals to bring essential surgical care closer to patients who need it most.
ISLC student leaders are an important part of that mission. They graduate with leadership skills, a global network of changemakers, and a deeper understanding of health equity. Many return home committed to strengthening their local health systems—some as medical volunteers, others as leaders within their communities—helping to expand access to care. Align Technology's philanthropic philosophy is to support organizations such as Operation Smile whose vision ties closely to Align's purpose of- transforming smiles and changing lives.
To learn more about Operation Smile's transformative partnership with Align Technology, click here: Align Technology.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, its integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
About Operation Smile
Operation Smile is a leading global nonprofit bridging the gap in access to essential surgeries and health care, starting with cleft surgery and comprehensive care. We provide medical expertise, training, mentorship, research and care through our dedicated staff and volunteers around the world, working alongside local governments, nonprofits and health systems, and supported by our generous donors and corporate partners. Visit operationsmile.org for more information.
Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN - Free Report) and Straumann Holding AG (SAUHY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Currently, both Align Technology and Straumann Holding AG are holding a Zacks Rank of #2 (Buy). Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
ALGN currently has a forward P/E ratio of 15.80, while SAUHY has a forward P/E of 32.31. We also note that ALGN has a PEG ratio of 1.54. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SAUHY currently has a PEG ratio of 2.41.
Another notable valuation metric for ALGN is its P/B ratio of 3.1. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, SAUHY has a P/B of 7.95.
These metrics, and several others, help ALGN earn a Value grade of B, while SAUHY has been given a Value grade of D.
Both ALGN and SAUHY are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ALGN is the superior value option right now.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Align Technology (ALGN - Free Report) Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
ALGN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.8; value investors should take notice.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $11.36 per share. ALGN also boasts an average earnings surprise of +7.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALGN should be on investors' short list.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Considering buying ALGN stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report second quarter 2026 financial results on Wednesday, July 29, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and wil.
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today responded to the European Commission’s June 30 press release announcing an investigation involving the Company based on a complaint made by an Align competitor.
Align Technology is committed to conducting business with integrity and in full compliance with global competition laws. We believe fair, lawful competition drives innovation, expands choice, and delivers better outcomes for doctors and patients. Our success in the teeth-straightening market is built on the strength of our products and services — quality, innovation, and customer experience — not on unfair practices, and we strongly dispute any suggestion to the contrary.
Align’s iTero intraoral scanning platform is designed to support an open and diverse digital dental ecosystem, and supports a wide range of clinical workflows, including implants, restorative dentistry, digital orthodontics, and clear aligner treatment. iTero generated scans can be freely exported to order aligners other than Invisalign aligners. Align maintains a scan acceptance policy designed to ensure clinical quality, patient safety, and system reliability, including validation requirements for digital file submissions and the operational resources needed to support consistent processing across workflows.
The iTero intraoral scanning platform is used globally by dental professionals across diverse treatment modalities, with millions of scans performed annually, reflecting its role in enabling a broad and competitive marketplace for digital dentistry solutions. Since 2018, the iTero scanner has been used by healthcare professionals to perform over 24 million restorative, wellness, and orthodontic scans.
The Commission’s step is purely procedural and allows it to gather information. It does not reflect a conclusion on the merits of the case, nor does it constitute an accusation or a finding of wrongdoing. The opening of an investigation does not prejudge its outcome.
Align is confident that any review of Align’s scanner and scan acceptance policies will reflect the robust and dynamic nature of the teeth-straightening market and believes its practices comply with applicable competition laws. We will cooperate fully and engage constructively with the Commission through the appropriate channels.
For nearly 30 years, Align Technology has helped transform a market long dominated by wires and brackets, offering meaningful choices to customers across Europe and around the world. By introducing innovative digital dentistry solutions that expand treatment possibilities for doctors and their patients, Align has helped doctors transform smiles and change lives for millions of patients, a testament to the value of innovation and better patient experience. What began as an innovation has grown into a widely accepted treatment category, one that now extends beyond Invisalign aligners and iTero scanners across a diverse and competitive ecosystem.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Align Technology (ALGN - Free Report) Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
ALGN is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.04; value investors should take notice.
Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.11 to $11.36 per share. ALGN boasts an average earnings surprise of +7.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALGN should be on investors' short list.
Investors interested in Medical - Dental Supplies stocks are likely familiar with Align Technology (ALGN) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Align Technology (ALGN - Free Report) Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
ALGN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. ALGN has a Momentum Style Score of B, and shares are up 3% over the past four weeks.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.11 to $11.36 per share. ALGN also boasts an average earnings surprise of +7.8%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ALGN should be on investors' short list.
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, following more than 20 years of distinguished service on Align’s Board of Directors. Mr. Larkin will continue to serve on the Board and as a member of the Nominating and Governance Committee through December 31, 2026, to support a smooth transition.
Kevin Conroy will succeed Mr. Larkin as Chairman of the Board, effective July 1, 2026. Mr. Conroy has served as an independent director since his appointment to the Board in December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026.
“On behalf of the entire Board and management team, I would like to express our deep gratitude to Ray for his extraordinary leadership, partnership, and enduring contributions to Align over more than two decades,” said Joe Hogan, Align Technology president and chief executive officer. “Ray has been instrumental in guiding Align through multiple phases of growth, innovation, and scale. His strategic insight, deep experience in healthcare, and unwavering commitment to strong governance have helped shape Align into the global leader it is today.”
Mr. Hogan continued, “We are pleased to welcome Kevin as our next Chairman. Kevin brings extensive experience as a board leader and recently as CEO of Exact Sciences prior to its acquisition by Abbott Laboratories in March 2026. He has demonstrated a strong track record of creating stockholder value, and deep expertise in healthcare, technology, and strategy. His leadership will help guide Align through our next chapter of growth and innovation.”
Mr. Larkin added, “It has been an honor to serve as Chairman of Align. I am incredibly proud of all that Align has achieved and confident in its continued leadership in digital dentistry. I look forward to supporting Kevin and the Board during this transition and seeing Align continue to transform smiles and improve patient outcomes around the world well into the future.”
Mr. Conroy said, “I am honored to be appointed Chairman of Align’s Board. Align has a strong foundation, an exceptional leadership team, and significant opportunities ahead. I look forward to working closely with Joe, the Board, and management to continue driving innovation, expanding access to digital orthodontics, and creating long-term value for our stockholders.”
ABOUT C. RAYMOND LARKIN, JR.
Mr. Larkin has served as a member of Align’s Board since 2004. He has decades of leadership experience in the medical device and healthcare industries, including serving as President and Chief Executive Officer of Nellcor Puritan Bennett, where he led the company’s growth to nearly $1 billion in revenue and helped establish pulse oximetry as a global standard of care. Throughout his tenure at Align, Mr. Larkin has provided strategic guidance across periods of significant growth and innovation, drawing on his extensive public and private company board experience and deep expertise in healthcare.
ABOUT KEVIN CONROY
Mr. Conroy has served as an independent director of Align since December 2023 and Chair of the Compensation and Human Capital Committee of the Board since January 2026. He brings extensive experience as a business, legal, and strategic leader, including serving as Chairman and Chief Executive Officer of Exact Sciences Corp. until its acquisition by Abbott Laboratories in March 2026, where he led the commercialization of Cologuard and grew the company to $3.25 billion in annual revenue while serving millions of patients. Prior to Exact Sciences, Mr. Conroy served as President and CEO of Third Wave Technologies and held leadership roles at GE Healthcare. He currently serves on the board of Abbott Laboratories and brings deep expertise in healthcare innovation, strategy, and governance.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Investors might want to bet on Align Technology (ALGN - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Align Technology basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Align Technology imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Align TechnologyThis maker of the Invisalign tooth-straightening system is expected to earn $11.32 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Align Technology. Over the past three months, the Zacks Consensus Estimate for the company has increased 4.2%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Align Technology to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Align Technology (ALGN - Free Report) Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
ALGN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.85; value investors should take notice.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $11.35 per share. ALGN also boasts an average earnings surprise of +7.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALGN should be on investors' short list.
Key Takeaways Align Technology is rolling out Invisalign DSP touch-up, Palatal Expander and ART into more markets. ALGN says iTero Lumina now makes up most scanners, as new tools streamline digital dentistry workflows.ALGN has $1.06B cash and no debt, but expects Invisalign ASP to fall about 1-2% in 2026. Align Technology’s (ALGN - Free Report) successful efforts to broaden the Invisalign business are poised to bring significant growth in the upcoming quarters. Also, iTero is gaining from the rapidly evolving intraoral scanning technology in the industry. A sound financial stability is beneficial for the stock as well. However, a lower average sell price (ASP) raises concerns about the company’s sales growth.
In the past year, this Zacks Rank #2 (Buy) company’s shares have lost 9.8% against 3.3% growth of the industry. In contrast, the S&P 500 composite has risen 31.3%.
The renowned medical device company has a market capitalization of $11.26 billion. ALGN projects a long-term estimated earnings growth rate of 11.2% compared with 9.9% growth of the industry. Its earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 7.8%.
Let’s delve deeper.
Upsides for ALGN StockInvisalign Business Expansion: Align Technology’s Invisalign portfolio offers orthodontic treatment to straighten teeth without metal braces. In recent quarters, the company has expanded Invisalign DSP touch-up cases to more countries and plans further rollouts, including in key APAC markets from 2026.
Among the recent developments, Align Technology continues to commercialize the Invisalign Palatal Expander with steady momentum in doctor submitters and shipments. The company commercially launched the Invisalign Palatal Expander System in India, Malaysia and Turkey. It also received the CE mark to market the Invisalign Palatal Expander system in most of Europe. The system also received regulatory approval in China.
Invisalign System with mandibular advancement featuring occlusal blocks is designed specifically to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. Align Technology expanded the commercial launch of this system to India, Malaysia, Philippines, Thailand, United States, Canada, Australia and New Zealand.
Following the successful launch of its inaugural Invisalign Advanced Restorative Treatment (“ART”) pilot in EMEA, the company has expanded the program into the United States, with laboratories and doctors undergoing training across several markets.
iTero in Focus: Align Technology’s iTero intraoral scanners, alongside its Exocad CAD/CAM software, continue to gain traction globally as key tools in digital dentistry. The iTero Lumina now represents the majority of iTero scanner system mix. It continues to pilot integrations, such as x-ray diagnostics with the iTero Lumina, in select international markets.
New innovations, including the Invisalign Outcome Simulator Pro, iTero Design Suite, and Align Oral Health Suite, are being used to enhance diagnostic, restorative and orthodontic workflows. The company remains focused on scaling adoption through clinical utility, automation, and seamless integration into restorative and ortho-restorative workflows.
Image Source: Zacks Investment Research
Recently, the company has introduced a set of enhancements to its iTero Digital Solutions platform — a comprehensive system that puts together intra-oral scanners, software tools and digital workflows used by dental and orthodontic practices.
Strong Solvency: With no debt on its balance sheet, Align Technology looks quite comfortable from the liquidity point of view. The company’s cash and cash equivalents totaled $1.06 billion at the end of first-quarter 2026.
Concern for ALGNUnfavorable Product Mix Shift Lowers ASP: Align Technology continues to experience pressure on Invisalign ASPs, particularly for comprehensive treatment options. In the fourth quarter, it experienced continued pressure on ASP, reflecting a combination of geographic mix, product mix and higher discounts. Looking ahead, the company expects ASP to reduce approximately 1-2% year over year in 2026.
ALGN Stock Estimate TrendThe Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved north 1.2% to $11.36 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $4.19 billion, suggesting a 3.8% rise from the year-ago reported number.
Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Quest Diagnostics (DGX - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 28.1% against the industry’s 12.5% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Quest Diagnostics, carrying a Zacks Rank #2, has an earnings yield of 5.7% compared with the industry’s 5.6% yield. Shares of the company have risen 6.6% compared with the industry’s 0.5% growth. DGX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.5%.
Phibro Animal Health, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.3%. PAHC’s shares have rallied 41.8% against the industry’s 32.8% decline over the past year.
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. As noted below, the presentations will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately one month.
Conference:
Stifel 2026 Jaws & Paws Conference
Date:
Thursday, May 28, 2026
Presentation:
8:00 – 8:30 a.m. ET
Location:
New York, NY
Speakers:
John Morici, EVP Global Finance and CFO
Shirley Stacy, VP Finance, Global Communications and IRO
Conference:
William Blair 46th Annual Growth Stock Conference
Date:
Wednesday, June 3, 2026
Presentation:
9:20 – 9:50 a.m. CT
Location:
Chicago, IL
Speakers:
Joseph Hogan, CEO
John Morici, EVP Global Finance and CFO
Shirley Stacy, VP Finance, Global Communications and IRO
Conference:
2026 Jefferies Global Healthcare Conference
Date:
Thursday, June 4, 2026
Presentation:
8:10 – 8:40 a.m. ET
Location:
New York, NY
Speakers:
John Morici, EVP Global Finance and CFO
Shirley Stacy, VP Finance, Global Communications and IRO
Conference:
Goldman Sachs 47th Annual Global Healthcare Conference
Date:
Monday, June 8, 2026
Presentation:
8:40 – 9:15 a.m. ET
Location:
Miami, FL
Speakers:
John Morici, EVP Global Finance and CFO
Shirley Stacy, VP Finance, Global Communications and IRO
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
On May 20, 2026, Align Technology Inc ALGN shares rose 5.3% today, closing at $163.42. The stock has been trading in a 52-week range from a low of $122.00 to a high of $208.31, reflecting significant volatility over the past year.
GF Value™ verdict: ALGN's current price is $163.42, while GF Value™ estimates fair value at $238.92, indicating it is 31.6% undervalued.GF Score™: 86/100, which is considered strong, suggesting a favorable long-term investment potential.Most notable signal: No insider transactions have occurred in the last three months, indicating a period of stability in insider activity. Is ALGN Overvalued or Undervalued? Align Technology Inc ALGN is currently trading significantly below its estimated fair value, as indicated by the GF Value™ of $238.92. This suggests that there is a substantial margin of safety for potential investors, as the shares are priced 31.6% lower than their intrinsic value. The GF Valuation label categorizes ALGN as "Significantly Undervalued," highlighting a potential opportunity for growth as the market corrects itself over time. However, it is essential to consider that while the undervaluation presents an opportunity, external factors such as market conditions and company performance should also be monitored to mitigate risks.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does ALGN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 27.4x 40.7x Forward P/E 14.4x - Align Technology's current P/E ratio of 27.4x is significantly below its 5-year median P/E of 40.7x, indicating that the stock is trading at a discount compared to its historical valuation. The forward P/E of 14.4x further reinforces this finding, suggesting a favorable outlook for earnings. This P/E analysis supports the GF Value™ verdict of undervaluation, indicating that the stock may be an attractive investment opportunity based on historical performance metrics.
What Does ALGN's GF Score™ Tell Us? Metric Rating GF Score™ 86 Financial Strength 7/10 Profitability 9/10 Growth 7/10 Valuation 4/10 Momentum 8/10 The GF Score™ of 86/100 indicates that Align Technology is positioned well across various dimensions. The strongest aspect is its profitability, rated 9/10, suggesting robust profit generation capabilities. However, the valuation rank of 4/10 indicates that while the company is undervalued, there may be some concerns regarding its price relative to fundamentals. The financial strength and growth ranks of 7/10 highlight a solid foundation for future performance, contributing to a favorable long-term outlook.
What Are Insiders Doing with ALGN Stock? There have been no insider transactions for Align Technology Inc in the last three months. This lack of activity might suggest that insiders are not currently buying or selling shares, which can indicate a period of confidence in the company's operations or a wait-and-see approach, reflecting stability in the company's leadership and prospects.
What This Means for Investors Based on the analysis of the GF Value™, Align Technology Inc ALGN is considered undervalued at its current price of $163.42 compared to its GF Value™ of $238.92. This presents a potential opportunity for investors looking for growth in the medical devices sector.
For the complete analysis, visit the Align Technology Inc ALGN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is ALGN's GF Score™?
ALGN's GF Score™ is 86, indicating a strong overall ranking based on key factors that have historically correlated with long-term returns.
Is ALGN overvalued or undervalued?
ALGN is currently undervalued, with a GF Value™ of $238.92 compared to its current price of $163.42, representing a significant opportunity for growth.
What is ALGN's P/E ratio?
Align Technology's P/E ratio (TTM) is 27.4x, which is substantially below its 5-year median P/E of 40.7x, indicating it is trading at a discount historically.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
BARCELONA, Spain & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights of its 2026 Invisalign® EMEA Ortho Summit, which brought together approximately 400 orthodontists and dental professionals from across Europe, the Middle East, and Africa (EMEA).
The three-day summit, held May 14–16, 2026 in Barcelona, Spain provided an immersive peer to peer learning experience focused on Align’s next generation digital technologies. These innovations are designed to address the most complex clinical indications for kids, teens and adults, including Class II malocclusions, while improving treatment precision, practice efficiency, and the overall patient experience.
Commenting on the 2026 Invisalign EMEA Ortho Summit, David Carr, Align Technology executive vice president and managing director, EMEA, said, “The Summit was designed to foster connection and collaboration with Invisalign providers. It was built around a simple idea: experience matters. Delivering effective and predictable outcomes, improving efficiency, and elevating the patient experience through digital orthodontics takes more than innovation, it requires experienced doctors who can apply it effectively in everyday practice. By bringing together Align integrated digital solutions and real-world clinical insights, the Invisalign EMEA Ortho Summit brought the region together, and provided an opportunity to collaborate with experts, expand clinical confidence, and share our latest innovations. I was also thrilled that we could offer participants early access to 3D Soft Tissue Animation, becoming the first Invisalign customers in the EMEA region to gain access to this innovation.”
Immersive Innovation Hub Showcases the Future of Orthodontics
At the center of the Summit was the Align Innovation Hub – an interactive end-to-end representation of a modern digital orthodontic practice. Designed as a “live” patient journey, the experience guided attendees from consultation through treatment to retention, demonstrating how digital tools can work seamlessly together.
The Hub featured:
A simulated clinical environment showcasing doctor-led consultations for teens and adults alongside integrated workflows Collaborative spaces for peer learning and exchange A gallery of current and upcoming innovations “The Innovation Hub showed how seamlessly everything can connect in a digital workflow,” said Dr. Jesús Veres, an orthodontist from Valencia, Spain, who attended the Summit. “Getting hands-on with each step of the process, from digital scanning to treatment planning to how we engage patients, gave me ideas I can take back to my practice to improve the experience for my patients.”
In addition to showcasing current Invisalign System innovations, the Summit’s Innovation Hub offered previews of several solutions expected by mid-2026, each aimed at bringing greater digital precision and consistency to traditionally manual procedures.* Highlights included:
The Invisalign Specifix™ Attachment System – a 3D printed attachment solution that combines attachments 3D-printed to the exact shape and size indicated in the doctor’s treatment plan with a novel bonding accessory for precise placement1. The Specifix system is designed to reduce variability in attachment size and placement, increase consistency, and streamline the attachment workflow. Invisalign® integrated buttons – a new digital approach to the small, bonded accessories used to anchor elastics and apply targeted forces during treatment. Digitally integrated buttons incorporate button planning into the ClinCheck® treatment planning workflow, replacing the standard manual process. With this digital approach, button type and position are determined within the software during treatment planning, helping to reduce chairside guesswork, improve placement accuracy, and deliver a more flexible, precise, and efficient bite correction. Invisalign® Palatal Expander with integrated hook features– a further evolution of Align’s 3D-printed palatal expander system designed to help doctors treat a broader range of patients with added flexibility. Building on the clinically effective2 Invisalign Palatal Expander (IPE) system, the new forward- and backward-facing integrated hooks are compatible with elastics3, offering intuitive enhancements to palatal expansion treatment. Invisalign clear aligner custom trimline option gives doctors greater control over aligner gingival margins to support improved aesthetics, comfort, and clinical flexibility. In cases where doctors feel there is insufficient retention, they can consider an extended scalloped trimline for short clinical crowns, erupting dentition cases, preferences for fewer attachments, extended tooth coverage in gingival recession and in extending to include the undercut of the clinical crowns. Integrated directly into the ClinCheck® digital treatment planning workflow, custom trim lines allow doctors to personalize aligner design based on individual patient anatomy and treatment. 3D Soft Tissue Animation, EMEA Ortho Summit participants also received early access to this recent innovation, becoming the first customers in the EMEA region. “We’re excited about the innovations previewed at the EMEA Summit and what they signal for the day-to-day reality of running a practice,” said Prof. Dr. Anton Demling, Uelzen, Germany, who participated as a speaker during the Summit. “Invisalign integrated buttons and the Specifix attachment system will take things that have traditionally required a lot of manual steps and variability and make them far more straightforward and consistent. That means less guesswork for teams, more predictable outcomes, and a noticeably better experience for patients. It’s a simpler way of working that just makes sense.”
Peer-Led Education and Clinical Exchange
The Summit program featured dozens of orthodontist-led sessions covering complex case treatment for cases such as impacted canines, digital workflow optimization, and patient engagement strategies. Interactive formats including panel discussions, breakout lecture sessions, and live demonstrations encouraged open dialogue and knowledge sharing among clinicians.
“What made this event especially valuable was the openness among colleagues and the quality of peer-to-peer learning,” said Dr. Nelly Dilkova, an orthodontist from Bulgaria, who also participated as a speaker. “The conversations went beyond innovation alone and focused on how we can use digital tools more effectively for our patients. Hearing colleagues share real clinical cases and practical workflows gave me valuable insights I can immediately apply in my practice. This outstanding atmosphere inspired new ways of thinking about the future of digital orthodontics.”
Advancing Integrated Digital Orthodontics with the Invisalign System
The Invisalign EMEA Ortho Summit reflects Align’s broader strategy to advance connected, digitally enabled orthodontic care. Ongoing investments in the Align™ Digital Platform continue to integrate scanning, visualization, treatment planning, appliance fabrication, treatment monitoring, and retention into a unified ecosystem designed to support doctors and enhance patient outcomes. Strategic areas of progress include:
Advancing digital orthodontic workflows that connect intraoral scanning, digital treatment planning, aligner fabrication, monitoring, and retention into seamless, data-driven experiences for doctors and patients. Continued leadership in digital manufacturing and 3D printing, enabling consistent, high-quality Invisalign aligner production at global scale while supporting speed and reliability for orthodontic practices. Ongoing investment in automation, designed to help doctors work more efficiently while maintaining clinical oversight and control as case complexity and practice scale increase. Expansion of diagnostic and visualization capabilities, supporting earlier intervention, improved patient understanding, and more confident treatment planning across a broader range of malocclusions and growth patterns. Scaling of integrated solutions, reflecting growing adoption of digitally connected orthodontic workflows in diverse practice models. Independent validation of the Invisalign Palatal Expander (IPE) – A clinical study by researchers at the University of Insubria, Italy found that the Invisalign Palatal Expander was shown to effectively widen the upper jaw by opening the natural growth seam in the palate, achieving bone and bite changes similar to a traditional metal Hyrax expander. IPE also delivered more controlled and predictable results than Hyrax, supporting its use as a reliable option for growing patients and highlighting its role as a key step toward fully digital orthodontic care4. Together, these and other planned innovations reinforce Align’s long‑term strategy to move beyond individual products toward connected experiences and outcomes, supporting prevention, early intervention, and digitally driven care delivery across orthodontic practices worldwide.
About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
* The availability of products may vary by market and is subject to applicable regulatory approvals and clearances. Please check with your local Align team for further information.
Based on bench testing conducted in August 2025 according to Design Verification on Specifix™ attachment volume precision (A035851). Data on File at Align Technology, as of January 28, 2026. Based on data from a multi-site US IDE (Investigational Device Exemption) clinical study (n=29 subjects, ages 7-10 years) of expansion treatment with Invisalign® Palatal Expanders. Data on file at Align Technology, as of October 30, 2023 Elastics are not supplied/provided by Align Technology, Inc Levrini L, Saran S, Imbesi E, Vanini I, Russo V, Rimoldi V, Carganico A, Giannotta N and Perugini M (2026), Skeletal and dentoalveolar effects on the midpalatal suture and maxillary arch assessed by occlusal radiographs and three-dimensional digital models in patients treated with Invisalign palatal expander and rapid palatal expander: a pilot study. Front. Dent. Med. 7:1757094. doi: 10.3389/fdmed.2026.1757094 More News From Align Technology, Inc.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Align Technology (ALGN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Align Technology is one of 884 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Align Technology is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALGN's full-year earnings has moved 3.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ALGN has moved about 4.4% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5.9% on a year-to-date basis. This means that Align Technology is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Carlsmed, Inc. (CARL - Free Report) . The stock is up 2.4% year-to-date.
For Carlsmed, Inc., the consensus EPS estimate for the current year has increased 21.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Align Technology belongs to the Medical - Dental Supplies industry, a group that includes 13 individual companies and currently sits at #65 in the Zacks Industry Rank. On average, stocks in this group have lost 8.4% this year, meaning that ALGN is performing better in terms of year-to-date returns.
In contrast, Carlsmed, Inc. falls under the Medical Info Systems industry. Currently, this industry has 41 stocks and is ranked #94. Since the beginning of the year, the industry has moved -24.1%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Align Technology and Carlsmed, Inc. as they could maintain their solid performance.
HYDERABAD, India & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced plans to open a new manufacturing facility in Hyderabad, India in 2027, create more than 300 direct jobs, and spend approximately $200 million in both capital and operational expense over the next several years. This new facility reflects Align’s strategy to get closer to customers and scale its operations to support high-growth markets like India, while strengthening its supply chain resilience and operational efficiency to drive shareholder value. It also demonstrates Align’s continued investments in aligner fabrication manufacturing and treatment planning capabilities in each of its regions, to better serve doctor customers and their patients, and contribute to their local economy through investment and employment.
“India represents an important growth market for Align, and we are excited about the opportunity to expand our global manufacturing network with a new facility in Hyderabad,” said Jitse Marrée, Align executive vice president, global operations. “This investment underscores our commitment to scaling our advanced manufacturing capabilities, supporting our doctor customers, and bringing the benefits of the Invisalign® System to more patients worldwide. Hyderabad’s strong talent base, infrastructure, and innovation ecosystem make it an ideal location for our next phase of growth.”
Align’s Hyderabad manufacturing facility will complement Align’s existing footprint in Hyderabad, which includes its Global Capability Center, the Align Innovation Center, further reinforcing the city’s strategic importance within Align’s global operations network. It would mark the company’s first manufacturing presence in India and its fourth globally. The proposed facility is expected to commence operations in 2027 and be margin accretive in the first year.
“We are proud to expand Align’s global manufacturing footprint with our first manufacturing facility in India and a new state-of-the-art site in Hyderabad,” said JunHo Han, Align executive vice president and managing director, Asia Pacific. “This investment reflects our long-term commitment to the Asia-Pacific region and builds on our continued expansion across key markets, where we have been investing in local teams, capabilities, and digital treatment planning infrastructure to support growing adoption of the Invisalign® System. The Hyderabad facility represents an important milestone as we scale our operations in high-growth markets and further strengthen our ability to support Invisalign-trained doctors and their patients. With this investment, we expect to enhance service levels across the region through more localized, customized support.”
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
About the Invisalign System
Invisalign clear aligners are a removable and transparent teeth-straightening solution produced using digital and 3D technologies. This type of solution differs from other orthodontic devices in that they are more comfortable and can be easily removed for eating or drinking. Used to treat minor to complex types of malocclusions, Invisalign clear aligners are replaced every one or two weeks, depending on a doctor’s recommendation, gradually moving teeth towards the projected final position.
Forward-Looking Statement
This news release contains forward-looking statements, including statements regarding the expected timing, scope, and benefits of Align Technology’s planned manufacturing facility in Hyderabad, India, including anticipated job creation, production capacity, and operational impact. Forward-looking statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.
Factors that may cause such differences include, but are not limited to:
changes in global or regional economic conditions; fluctuating customer demand; regulatory and approval processes; construction and operational timelines; supply chain disruptions; competitive dynamics; and other risks detailed in Align Technology’s filings with the Securities and Exchange Commission. Align undertakes no obligation to update forward-looking statements except as required by law.
Why These 3 Tech Stocks Could Be the Best Opportunities You're OverlookingAlign Technology NASDAQ: ALGN executives highlighted product innovation, financing initiatives and international expansion as key growth drivers during a discussion at the 2026 Stifel Jaws & Paws Conference.
Chief Financial Officer John Morici, joined by Shirley Stacy, vice president of finance, global communications and investor relations, spoke with Stifel healthcare managing director Jonathan Block following a technology update the company held the prior day. Morici said Align is moving beyond individual products toward broader treatment “solutions,” including enhancements to its Invisalign Palatal Expander and mandibular advancement products.
Get Align Technology alerts:
Buy the Dip? These Earnings Misses Offer Long-Term UpsideMorici said the company is adding features such as hooks and buttons to the palatal expander and developing products that can move teeth while also addressing jaw and skeletal issues. He said direct fabrication technology helps support that shift by making it easier for doctors to treat multiple issues at the same time, particularly in teenagers.
Financing and Conversion Initiatives Remain a Focus Morici said Align is also emphasizing “active conversion” strategies that it has learned from dental service organization partners and large practices. Those strategies include working with outside financing companies such as HFD to provide patients with more affordable monthly payment options and improve treatment acceptance rates.
MarketBeat Week in Review: 12/25 - 12/29He said Align typically pilots new initiatives, learns from the pilots and then moves toward broader releases. That approach applies to both ortho-restorative initiatives involving labs and patient financing programs. Morici said many of those efforts were piloted last year and have begun rolling out into this year.
Direct Fabrication Expected to Scale Over Time Discussing direct fabrication, Morici said the technology remains dilutive to gross margins this year, but the company expects it to become more neutral as volume scales. He said reaching more than 10% to 15% of volume for directly fabricated products could allow the company to offset the initial margin drag.
Morici said the main margin opportunity comes from lower material costs compared with traditional manufacturing, where Align must create and discard a negative mold. He said the company initially is scaling direct fabrication through products with attachments and specialty retainers, before moving into broader retention products and then aligners. He said aligners could become more regular direct fabrication products in the later part of next year.
Morici said direct fabrication for aligners will require FDA approval, and Align is in the process of working through that. He said biocompatibility and other requirements are “well along,” and that the bigger focus is scaling the resin and manufacturing processes.
North America Remains Challenging, DSOs Grow Faster Morici said the U.S. represents more than 40% of Align’s business and that the company has been operating in a low consumer confidence environment for several quarters. He said recent changes in consumer confidence readings have not materially changed the company’s business environment.
In North America, Morici described a split between DSOs and more traditional independent practices. He said U.S. DSOs are growing at double-digit rates by using more active conversion strategies, including scanning every patient, showing treatment visualizations, offering competitive pricing and providing financing options that lower monthly payments.
By contrast, Morici said some independent or retail-oriented doctors have taken a more passive approach and have not grown as much. Still, he said those practices are becoming “less negative,” and North America was about flat in the first quarter against a tough comparison from the prior year. Morici said the expectation is for North America to return to growth as initiatives such as financing and conversion tools gain traction, though he acknowledged macroeconomic pressures including inflation remain a factor.
International Markets Continue Double-Digit Growth Outside North America, Morici said Align continues to see double-digit growth across APAC, EMEA and Latin America. He said growth is not uniform across every country, but larger and emerging markets are driving results, including Turkey, India, Eastern Europe and Southeast Asia.
Stacy added that continued expansion outside the United States remains an important opportunity, describing emerging markets as “still very fertile.”
Morici said Align benefits from underpenetrated markets and a direct sales force focused on bringing more doctors into the company’s ecosystem, training them, reducing churn and increasing utilization.
Margins, ASPs and New Offerings Morici said Align expects 100 basis points of margin expansion this year, aided by restructuring, but he also pointed to additional opportunities in gross margin and operating expense leverage. He said products without refinements, including “no AA” or “Zero AA” style offerings, carry higher gross margins because they rely on more efficient treatment planning and do not include built-in refinements.
He said Align is also pursuing productivity improvements in manufacturing, including resin, labor and freight cost reductions. Morici said the company posted 250 basis points of operating margin improvement and 200 basis points of gross margin improvement in the first quarter excluding foreign exchange effects.
On research and development spending, Morici said R&D as a percentage of revenue should begin to normalize over time as products move closer to commercialization and revenue from those products increases.
Morici said average selling prices are typically affected by mix, including country mix and product mix, and that Align usually sees one to two points of ASP pressure from those factors excluding foreign exchange. For 2026, he said foreign exchange and a U.K. VAT-related benefit are expected to reduce that pressure closer to about 1%.
Discussing the no-refinement product, Morici said it is intended in part to compete more effectively with wires and brackets by narrowing the price gap for doctors. He said a doctor who might pay about $350 in material costs for wires and brackets could face a much higher cost for Invisalign, but the no-refinement product may be priced in the $700 to $800 range depending on discounts. He said doctors can purchase refinements as needed, with a U.S. refinement costing $170.
Morici said the product is designed to win more share from wires and brackets while also helping regain volume from doctors who had shifted to lower-cost clear aligner competitors. He said some competitors have increased prices, while Align has not.
For the second quarter, Morici said Align typically sees sequential revenue growth of 3% to 4% from the first quarter to the second quarter. This year, he said the midpoint of the company’s second-quarter guidance implies about 1% sequential growth, reflecting prudence around geopolitical uncertainty and patient decisions.
Morici also said DSOs account for about 35% of Align’s North America volume and about 25% of global volume. He said their gross margins are comparable to the broader business and that DSOs can be favorable from an operating margin standpoint because they handle training, local marketing and other activities. He described DSOs as a “force multiplier” for Align.
About Align Technology NASDAQ: ALGNAlign Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.
The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Align Technology Right Now?Before you consider Align Technology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Align Technology wasn't on the list.
While Align Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
It has been about a month since the last earnings report for Align Technology (ALGN - Free Report) . Shares have lost about 1.6% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Align Technology due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.
ALGN Q1 Earnings and Revenues Beat, Margins RiseAlign Technology, Inc. (ALGN - Free Report) reported first-quarter 2026 non-GAAP earnings of $2.58 per share, which rose 21.1% year over year and beat the Zacks Consensus Estimate by 14.41%. Total revenues of $1.04 billion increased 6.2% from the year-ago quarter and beat the consensus mark by 1.81%.
The results were supported by record Invisalign clear aligner shipments of 685.7 thousand cases, up 6.7% year over year, reflecting double-digit growth in EMEA, APAC and Latin America and continued stability in North America.
ALGN’s Clear Aligner Strength Drives Top-Line GrowthClear Aligner revenues rose 7.4% year over year to $856.0 million, supported by higher volumes and increased average selling prices. Management also attributed the year-over-year increase to favorable foreign exchange, price actions and lower net deferrals, partially offset by higher discounts and a mix shift toward lower-priced countries and products.
On the demand side, shipments to orthodontists and GP dentists increased 7.4% and 5.6%, respectively, year over year. By patient cohort, Invisalign adult shipments increased 7.8% year over year, while teen and kid patients improved 4.8%, aided by continued adoption of Invisalign First, the Invisalign Palatal Expander and mandibular advancement with occlusal blocks.
Align Sees Mixed Scanner Seasonality, Solid Year-Over-Year GainImaging Systems and CAD/CAM Services revenues increased 0.9% year over year to $184.1 million. However, the segment’s sale declined sequentially as first-quarter capital equipment seasonality weighed on results.
Management noted that the number of scanners sold to new doctors increased by double digits year over year, while the installed base of active scanners exceeded 125,000 globally during the quarter. The company highlighted double-digit year-over-year revenue growth for exocad, reinforcing its strategy to integrate orthodontics and restorative dentistry workflows.
ALGN’s Margins Improve Y/Y, Legal Costs Hit ExpensesFirst-quarter gross margin expanded 160 basis points (bps) year over year to 70.8%, primarily reflecting operational efficiencies and higher Clear Aligner ASP. The company noted foreign exchange was an unfavorable 0.4-point headwind to gross margin on a year-over-year basis. On a non-GAAP basis, gross margin was 71.8%, also up 160 bps.
Operating expenses increased 8.3% year over year to $594.6 million, caused mainly by legal settlement costs and higher employee compensation. GAAP operating margin improved 20 bps year over year to 13.6%, while non-GAAP operating margin expanded 240 bps to 21.5%, reflecting the benefit of excluding items, such as stock-based compensation and legal settlement costs.
ALGN’s Cash Flow Rises, Buybacks Stay in FocusALGN ended the quarter with $1.06 billion in cash and cash equivalents compared with $1.09 billion at the end of 2025. Operating cash flow totaled $151.0 million in the quarter, and free cash flow was $120.3 million after $30.8 million of capital expenditures, largely tied to investments in manufacturing capacity and facilities.
Regarding capital allocation, the company said it finished its earlier $200 million stock repurchase program between August 2025 and January 2026, with $800 million still available under its $1.0 billion authorization as of March 31, 2026. The company further disclosed plans for an additional share buyback of up to $200 million over a six-month period beginning on or about May 1, 2026.
ALGN Reaffirms 2026 View, Sets Q2 Revenue RangeFor full-year 2026, Align reaffirmed its outlook for worldwide revenue growth of 3-4% year over year and Clear Aligner volume growth in the mid-single digits. The Zacks Consensus Estimate for 2026 revenues is currently pegged at $4.18 billion, implying 3.5% growth. The company continues to expect GAAP operating margin slightly below 18.0% and a non-GAAP operating margin of about 23.7%, along with capital expenditures of $125-$150 million.
For the second quarter of 2026, management expects worldwide revenues of $1.040-$1.060 billion, up about 3-5% year over year. The Zacks Consensus Estimate for the metric projects 3.8% growth to $1.05 billion. The company forecasts sequential and year-over-year growth in Clear Aligner volume, with ASP expected to stay flat on both a sequential and annual basis. Systems and Services revenues are expected to rise sequentially.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.
VGM ScoresCurrently, Align Technology has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Align Technology has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry PlayerAlign Technology belongs to the Zacks Medical - Dental Supplies industry. Another stock from the same industry, West Pharmaceutical Services (WST - Free Report) , has gained 8.1% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
West Pharmaceutical reported revenues of $844.9 million in the last reported quarter, representing a year-over-year change of +21%. EPS of $2.13 for the same period compares with $1.45 a year ago.
For the current quarter, West Pharmaceutical is expected to post earnings of $2.08 per share, indicating a change of +13% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.2% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for West Pharmaceutical. Also, the stock has a VGM Score of F.
$300,000 in Research Grants Awarded as Part of its Ongoing Annual Research Awards Program
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program.
“Research and clinical evidence continue to be at the core of advancing science, which furthers innovation and clinical treatments,” said Dr. Mitra Derakhshan, Align executive vice president, chief clinical officer, global treatment planning and clinical services. “We remain committed to supporting university research worldwide and the meaningful impact it drives in shaping the future of the orthodontic and dental profession.”
The Americas research award recipients for 2026 are:
University of Florida (Gainesville, FL) Primary Investigator - Dr. Isil Aras University of Florida (Gainesville, FL) Primary Investigator - Dr. Sarah Hisham Abu Arqub Southern Illinois University (Edwardsville, IL) Primary Investigator - Dr. Feras Al Khatib University of Alabama (Birmingham, AL) Primary Investigator - Dr. Navdeep Bhusri The European research award recipients for 2026 are:
Francisco de Vitoria University (Madrid, Spain) Primary Investigator - Dr. Iván Nieto Sánchez Johann Wolfgang Goethe University (Frankfurt, Germany) Primary Investigator - Dr. Babak Sayahpour University of Insubria (Varese and Como, Italy) Primary Investigator - Dr. Luca Levrini Vita-Salute San Raffaele University (Milan, Italy) Primary Investigator - Dr. Andrea Boggio The Asia Pacific research award recipients for 2026 are:
Wuhan University (Wuhan, China) Primary Investigator - Dr. Sanjie Yeweng Sichuan University (Chengdu, China) Primary Investigator - Dr. Juan Li Taipei Medical University (Taipei City, Taiwan) Primary Investigator - Dr. Daniel De-Shing Chen Shandong University (Jinan, China) Primary Investigator - Dr. Hui Chen “The scope of research supported through this program highlights the important role of scientific inquiry in advancing dentistry,” said John Morton, Align vice president, technical fellow. “We are proud to support investigators whose work can deepen clinical understanding, inform treatment approaches, and ultimately improve patient care worldwide.”
The funded research studies cover a wide range of topics, including:
Apical root resorption during anterior retraction, early and late restoration of maxillary laterals during aligner treatment, evaluation of the Invisalign Palatal Expander and traditional expanders in mixed dentition, white spot lesion activity between fixed appliances and aligners, stability of alignment in retention with various protocols, anterior tooth movement with lingual versus buccal attachments, and characteristics of enamel during aligner treatment by using scanning electron microscopy and optical microscopy.
All award applications received were first reviewed and prioritized in a blind evaluation by an independent academic committee. The final recipients were then determined by Align Technology.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 299.5 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 22.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Why These 3 Tech Stocks Could Be the Best Opportunities You're OverlookingAlign Technology NASDAQ: ALGN executives used a William Blair investor presentation to emphasize the company’s broader digital dentistry platform, positioning Invisalign as part of a workflow that spans consumer engagement, scanning, treatment planning, monitoring and retention.
President and CEO Joe Hogan said Align’s competitive position is not based solely on clear aligners, pointing instead to the company’s ability to connect consumers with doctors and support a digital process from diagnosis through treatment. He said 95% of Align cases are now scanned, compared with 5% about 10 years ago.
Get Align Technology alerts:
Buy the Dip? These Earnings Misses Offer Long-Term UpsideHogan said the company can produce treatment plans quickly for a growing portion of patients, with about 20% to 25% of cases completed live in the chair and moved toward manufacturing with limited back-and-forth. He said many ClinCheck cases that previously took up to two weeks are now completed in a day, and it is “odd” to see them take more than two or three days.
Executives Highlight Teen and Early-Intervention Opportunity Hogan said roughly 75% of global malocclusions involve crooked teeth, but the market is weighted toward teens while Align’s business is weighted toward adults. He said Align’s case mix is approximately 73% adults and 23% teens, a gap he attributed to orthodontists’ continued use of wires and brackets rather than clinical limitations of Invisalign.
MarketBeat Week in Review: 12/25 - 12/29Align is targeting younger patients through early-intervention products, including Invisalign Teen and Invisalign Palatal Expander. Hogan described the younger “tween” population as the company’s most compliant patient group because children at that age are still responsive to parental direction and bone is more malleable.
Hogan said Invisalign Palatal Expander is a removable device and the first 3D-printed medical orthodontic device of its kind. He said the product can provide up to nearly seven millimeters of expansion, while the teen product can provide five millimeters. Align also expects a new 3D-printed Vivera retainer to begin entering the market in the third and fourth quarters of this year, according to Hogan.
AI and ClinCheck Are Central to Treatment Planning Chief Financial Officer John Morici said Align’s ClinCheck platform is supported by the company’s experience with more than 23 million cases, allowing it to learn doctors’ treatment tendencies and apply those preferences to new cases. He said the goal is to provide a treatment plan while the patient is still in the chair, helping doctors have a more immediate conversation with potential patients.
Hogan said Align has invested heavily in ClinCheck since moving the system from individual computers to servers and the cloud in 2021. He said features such as ClinCheck Live Plan, Plan Editor and global clinical preferences allow doctors to adjust plans, incorporate their own protocols and send cases to manufacturing faster.
Morici said the company is also using AI tools in Invisalign Virtual Care to monitor patient progress. Hogan said virtual monitoring can reduce patient office visits by about 30% to 35% by allowing patients to submit weekly images and receive guidance on whether they are tracking to plan.
Digital Dentistry and General Practitioner Adoption Hogan said the general practitioner opportunity is significant because many dentists historically were not taught how to move teeth in dental school. Align is trying to bring those capabilities to general dentists through sales, training and key opinion leaders.
Executives framed malocclusion treatment as part of broader oral health rather than only aesthetics. Hogan said teeth that do not align properly can wear over time, and Morici said digital scans can help dentists show patients issues such as tooth wear, cavities or restorative needs.
Hogan also emphasized visualization as a key part of modern dentistry, saying patients should be able to see scans and understand what is happening with their teeth. Morici said visualization tools, including before-and-after treatment videos, can help doctors improve conversion. Hogan said showing video can produce a roughly 50% higher close rate.
Restorative Dentistry and exocad Integration Align also discussed its advanced restorative treatment initiative, Invisalign Art, which uses tooth movement to make some restorative procedures less invasive. Hogan said the approach can help move teeth “out of harm’s way” before procedures such as veneers or implants, potentially reducing the need to grind down enamel.
Hogan tied the initiative to Align’s 2020 acquisition of exocad, a software business used by dental labs. He said Align uses exocad to embed ClinCheck tooth movement into restorative planning so labs and doctors can present patients with options, including taking additional months to move teeth rather than grinding them down.
Business Models Focus on Conversion and Flexibility Morici said Align is also developing business models intended to help doctors drive patient conversion, especially in the current economic environment. He highlighted a doctor subscription program that allows practices to commit to a certain number of cases or aligners, including aligners used for retention or minor “touch-up” cases.
Morici also pointed to patient financing as a way to reduce “financial friction.” He said Align does not take the end risk on financing but partners with external companies, citing HFD as an example. He said such arrangements can offer high approval rates, pre-qualification and upfront cash for practices while reducing collection burdens.
The company also discussed a comprehensive product without refinements included upfront, giving doctors flexibility to purchase additional service later if needed. Morici said the model started with Dental Service Organizations and has helped drive utilization by lowering initial pricing for customers that do not want service included at the outset.
Morici said Align is focused on using technology, product options and financing tools to drive conversion, particularly in the U.S. market. “You want to hit those potential patients in the moment and drive that conversion,” he said.
About Align Technology NASDAQ: ALGNAlign Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.
The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Align Technology Right Now?Before you consider Align Technology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Align Technology wasn't on the list.
While Align Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Why These 3 Tech Stocks Could Be the Best Opportunities You're OverlookingAlign Technology NASDAQ: ALGN CFO John Morici said the company continues to navigate a challenging but stable demand environment, with international markets and dental service organizations offsetting pressure in parts of North America.
Speaking at the Jefferies Global Healthcare Conference in a fireside chat moderated by Jefferies analyst Mike Sarcone, Morici said macroeconomic conditions have been broadly consistent over the past several quarters, including the effects of inflation. He said Align has seen double-digit growth outside North America, including in Asia-Pacific, EMEA and Latin America, while dental service organizations, or DSOs, in North America have also been growing at a double-digit rate.
Get Align Technology alerts:
Buy the Dip? These Earnings Misses Offer Long-Term UpsideThe area of pressure, Morici said, remains the U.S. and North America retail channel among independent doctors. In that environment, Align is focused on helping doctors convert interested patients into treatment starts.
“Where you have to go and really try to drive that conversion is be much more active,” Morici said, adding that the company is using tools and tactics to help doctors move patients “from being interested in treatment to actually going into treatment.”
Company Reiterates Focus on Profitable Growth MarketBeat Week in Review: 12/25 - 12/29Morici said Align’s full-year outlook reflects expectations for 3% to 4% growth and a 100-basis-point improvement in operating margin. He said the company has taken cost actions from last year into this year to improve productivity.
In the first quarter, Morici said Align delivered a 250-basis-point improvement in operating margin on an ex-FX basis. He said volume increases should provide additional operating margin leverage.
Asked about second-quarter assumptions, including potential effects from conflicts in the Middle East, Morici said Align’s typical sequential revenue increase from the first to second quarter has historically been around 3% to 4%, helped by North America’s teen season, stronger volume in Western Europe and improved systems and services demand. For the current framework, he said the midpoint was set at 1% sequential growth, reflecting prudence in an uncertain environment.
Comp Zero Offering Aims to Expand Invisalign Utilization Morici discussed Align’s comprehensive product with no refinements, which Sarcone referred to as “Comp Zero.” He said the product reflects advances in Align’s technology compared with earlier comprehensive offerings that included unlimited refinements over five years.
Morici said earlier versions were designed to give doctors confidence that they could reach a final outcome, but improvements in technology now allow some cases to be completed with no refinements or one refinement. The no-refinement product is being tested and adopted across DSOs, where Morici said doctors are showing increasing usage.
He described the product as helping Align win “gray areas,” particularly when orthodontists are deciding whether to use wires and brackets or Invisalign. Morici said the pricing is closer to the material cost of wires and brackets than Align’s comprehensive unlimited product, while also being competitive with other clear aligner offerings.
Morici said versions of the product are available in North America, Europe and Asia-Pacific, and he said he expects it to be broadly rolled out by the end of the year. He also noted that Align’s “3-and-3” product, which includes three years of treatment and three refinements, became the company’s top-selling product after being introduced about three and a half years ago.
From a margin standpoint, Morici said products with fewer refinements can carry attractive gross margins because there is less back-and-forth after the initial shipment. If refinements are needed later, doctors pay for them separately.
Financing Programs Target Patient Conversion Align is also emphasizing financing options to help doctors convert patients. Sarcone referenced Align’s HFD partnership and Smile Advance program, including a $99 down payment and 0% APR for 24 months, and said more than 6,000 offices were enrolled.
Morici said Align is already seeing benefits from HFD and other financing programs, particularly in a more challenging market. He said the goal is to give patients low down payment options and, where possible, little or no interest, while helping doctors receive much of their cash upfront and outsource collections.
Morici emphasized that the financing is not on Align’s balance sheet. Instead, Align’s role is to help facilitate adoption by educating doctors and equipping sales representatives to present the programs.
He said DSOs can move faster on programs like these because they often operate with a top-down approach. Independent doctors also represent an opportunity, though Morici said general dentists may be more accustomed to patient financing than orthodontists, who often use internal pay-as-you-go models.
Practice Management Integrations and Lab Pilots Morici said Align is working to integrate with practice management platforms to reduce handoffs in the patient journey. He cited the company’s integration with Greyfinch as producing immediate benefits by improving patient flow, appointment scheduling and follow-up.
He said Align Link integrations with additional practice management systems are on the company’s roadmap, with Align proceeding system by system. Morici said the goal is to connect interested consumers with doctors, move them through scans and visualizations, and support financing where appropriate.
Morici also highlighted pilots with dental labs aimed at restorative workflows. He said Align’s view is that teeth should be moved before restorative procedures when appropriate, potentially preserving more healthy tooth structure before veneers or other restorative work.
The lab model, Morici said, allows labs to act similarly to distributors. Align charges for the case, while labs can add a markup for treatment planning, education and related services provided to their dentist networks. He said this creates revenue opportunities for labs and doctors while generating incremental volume for Align.
Morici said there are about 2 million general dentists globally, and Align currently sells to roughly 5% of them. He also said there are more than 30,000 labs worldwide, and many general dentists have existing trusted relationships with labs. Align’s exocad business, acquired six years ago, is part of the company’s effort to support these workflows.
For Align, Morici said the lab-related cases are typically moderate or minimal movement cases, often 26 stages or fewer and with no refinements, making the margin profile attractive. He said the company views the program as incremental and a potential way to access doctors who have not previously offered Invisalign or have done only one or two cases.
About Align Technology NASDAQ: ALGNAlign Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.
The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Align Technology Right Now?Before you consider Align Technology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Align Technology wasn't on the list.
While Align Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
After reaching an important support level, Align Technology (ALGN - Free Report) could be a good stock pick from a technical perspective. ALGN surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first marker of an up or down trend.
ALGN has rallied 7.4% over the past four weeks, and the company is a Zacks Rank #1 (Strong Buy) at the moment. This combination suggests ALGN could be on the verge of another move higher.
The bullish case solidifies once investors consider ALGN's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 6 higher, while the consensus estimate has increased too.
Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ALGN for more gains in the near future.
